State Key Laboratory of Organ Failure Research, Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, People's Republic of China.
Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, People's Republic of China.
J Fluoresc. 2017 Jul;27(4):1479-1485. doi: 10.1007/s10895-017-2087-1. Epub 2017 Apr 20.
Glypican-3(GPC3), an oncofetal protein, is a potential novel marker for hepatocellular carcinoma (HCC). In this study, we attempted to establish a new method to detect serum GPC3 using the antibodies identified in our previous research, and then evaluated its clinical application for the diagnosis of HCC. Herein, a sandwich time-resolved fluorescence immunoassay (TRFIA) for detecting serum GPC3 was developed. The detection limit, analytical recovery, specificity and precision of the proposed TRFIA assay were satisfactory. A total of 415 patients were collected and divided into seven groups: hepatocellular carcinoma (101), colorectal cancer (67), gastric cancer (44), esophageal cancer (15), cirrhosis (55), hepatitis (61), normal liver (72). Using this proposed method, the concentration of serum GPC3 in these clinical samples was detected. The results demonstrated that the levels of GPC3 in serum from HCC patients were significantly higher than that in others. Compared with the results of chemiluminescence immunoassay (CLIA), a high consistency (Kappa =0.84) was observed. Thus, an effective, sensitive and reliable TRFIA-GPC3 kit for diagnosing HCC was successfully developed. It offers a suitable alternative to existed methods of determining GPC3 and is expected to be used in clinic in the future.
磷脂酰聚糖-3（GPC3）是一种癌胚蛋白，是肝细胞癌（HCC）的潜在新型标志物。在本研究中，我们试图建立一种使用我们之前研究中鉴定的抗体检测血清 GPC3 的新方法，然后评估其用于 HCC 诊断的临床应用。在此，开发了用于检测血清 GPC3 的夹心时间分辨荧光免疫分析（TRFIA）。所提出的 TRFIA 分析的检测限、分析回收率、特异性和精密度均令人满意。共收集了 415 名患者，并将其分为七组：肝细胞癌（101）、结直肠癌（67）、胃癌（44）、食管癌（15）、肝硬化（55）、肝炎（61）、正常肝脏（72）。使用该方法检测了这些临床样本中血清 GPC3 的浓度。结果表明，HCC 患者血清中 GPC3 的水平明显高于其他患者。与化学发光免疫分析（CLIA）的结果相比，观察到高度一致性（Kappa=0.84）。因此，成功开发了用于诊断 HCC 的有效、灵敏和可靠的 TRFIA-GPC3 试剂盒。它为确定 GPC3 提供了一种替代方法，有望在未来在临床上使用。
